These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 31148288)

  • 1. Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American survey.
    Castañeda-Hernández G; Sandoval H; Coindreau J; Rodriguez-Davison LF; Pineda C
    Pharmacoepidemiol Drug Saf; 2019 Aug; 28(8):1035-1044. PubMed ID: 31148288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PANLAR consensus statement on biosimilars.
    Kowalski SC; Benavides JA; Roa PAB; Galarza-Maldonado C; Caballero-Uribe CV; Soriano ER; Pineda C; Azevedo VF; Avila-Pedretti G; Babini AM; Cachafeiro-Vilar A; Cifuentes-Alvarado M; Cohen SB; Díaz PE; Soto LD; Encalada C; Garro B; Sariego IAG; Guibert-Toledano M; Rodriguez VJK; Lopez MEL; Ortega AP; Russell AS; Santos-Moreno P; Terán IS; Vargas A; Vásquez G; Xavier RM; Firedman DXX; Mysler E; Kay J
    Clin Rheumatol; 2019 May; 38(5):1485-1496. PubMed ID: 30915652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America.
    de la Cruz C; de Carvalho AV; Dorantes GL; Londoño Garcia AM; Gonzalez C; Maskin M; Podoswa N; Redfern JS; Valenzuela F; van der Walt J; Romiti R
    J Dermatol; 2017 Jan; 44(1):3-12. PubMed ID: 27461455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Regulation of Biosimilars in Latin America.
    Garcia R; Araujo DV
    Curr Rheumatol Rep; 2016 Mar; 18(3):16. PubMed ID: 26951254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?
    Azevedo VF; Babini A; Caballero-Uribe CV; Castañeda-Hernández G; Borlenghi C; Jones HE
    J Clin Rheumatol; 2019 Mar; 25(2):91-100. PubMed ID: 30059414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
    Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view.
    Pineda C; Caballero-Uribe CV; de Oliveira MG; Lipszyc PS; Lopez JJ; Mataos Moreira MM; Azevedo VF
    Clin Rheumatol; 2015 Apr; 34(4):635-40. PubMed ID: 25673060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA Biosimilar Action Plan: could improving pharmacovigilance of biologics improve patient and physician confidence in biosimilars?
    Jordan JB; Christl L
    Expert Opin Drug Saf; 2020 Mar; 19(3):229-232. PubMed ID: 32098520
    [No Abstract]   [Full Text] [Related]  

  • 10. Regulatory challenges with biosimilars: an update from 20 countries.
    Kang HN; Thorpe R; Knezevic I; Casas Levano M; Chilufya MB; Chirachanakul P; Chua HM; Dalili D; Foo F; Gao K; Habahbeh S; Hamel H; Kim GH; Perez Rodriguez V; Putri DE; Rodgers J; Savkina M; Semeniuk O; Srivastava S; Tavares Neto J; Wadhwa M; Yamaguchi T
    Ann N Y Acad Sci; 2021 May; 1491(1):42-59. PubMed ID: 33222245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iraqi regulatory authority current system and experience with biosimilars.
    Al-Kinani KK; Ibrahim MJ; Al-Zubaidi RF; Younus MM; Ramadhan SH; Kadhim HJ; Challand R
    Regul Toxicol Pharmacol; 2020 Nov; 117():104768. PubMed ID: 32861742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars: Implications for health-system pharmacists.
    Lucio SD; Stevenson JG; Hoffman JM
    Am J Health Syst Pharm; 2013 Nov; 70(22):2004-17. PubMed ID: 24173009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmarketing Safety of Biosimilars: Current Status, Challenges, and Opportunities in the Spontaneous Reporting System.
    Singh A; Kalaivani M; Srivastava S; Goyal RK; Gupta SK
    Ther Innov Regul Sci; 2020 May; 54(3):667-680. PubMed ID: 33301154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.
    Uhlig T; Goll GL
    Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv49-iv62. PubMed ID: 28903542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilar safety factors in clinical practice.
    Reinisch W; Smolen J
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars - terms of use.
    Declerck P; Mellstedt H; Danese S
    Curr Med Res Opin; 2015 Dec; 31(12):2325-30. PubMed ID: 26397731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory considerations in biosimilars: Latin America region.
    Rathore AS; Bhargava A
    Prep Biochem Biotechnol; 2021; 51(2):201-206. PubMed ID: 33529091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective.
    Kurki P; Barry S; Bourges I; Tsantili P; Wolff-Holz E
    Drugs; 2021 Nov; 81(16):1881-1896. PubMed ID: 34596876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?
    Oza B; Radhakrishna S; Pipalava P; Jose V
    J Postgrad Med; 2019; 65(4):227-232. PubMed ID: 31571620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars: A Multidisciplinary Perspective.
    Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
    Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.